Novartis Pharmaceuticals Canada Inc.

Aug 20, 2024

Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy

Jul 08, 2024

Novartis Canada launches $500,000 funding initiative to improve health equity in Canada

May 27, 2024

NOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIP

Dec 16, 2020

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)1

Aug 13, 2020

PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer

Apr 16, 2020

Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment

Mar 03, 2020

Novartis receives Health Canada approval for Mayzent(TM) (siponimod) to treat secondary progressive multiple sclerosis with active disease